Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.51 |
| ▸ | FEN1 | P39748 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634326 | 1.00 | ALDH1A1 (0.55) | ALDH1A1HPGDHSD17B3MAPTMEN1 | |
| SCHEMBL634225 | 0.98 | ALDH1A1 (0.56) | ALDH1A1HPGDHSD17B3MAPTMEN1 | |
| SCHEMBL633895 | 0.93 | ALDH1A1 (0.57) | ALDH1A1HPGDHSD17B3MAPTHTT | |
| SCHEMBL19757423 | 0.90 | HSD17B3 (0.55) | ALDH1A1HPGDHSD17B3MAPTMEN1 | |
| SCHEMBL13085731 | 0.88 | HSD17B3 (0.62) | ALDH1A1HSD17B3MAPTMEN1HTT | |
| SCHEMBL634434 | 0.86 | ERCC5 (0.57) | ALDH1A1HPGDHSD17B3MAPTMEN1 | |
| SCHEMBL7388180 | 0.85 | ERCC5 (0.53) | ALDH1A1HPGDMAPTMEN1HTT | |
| SCHEMBL7388254 | 0.85 | ERCC5 (0.53) | ALDH1A1HPGDMAPTMEN1HTT | |
| SCHEMBL5546398 | 0.84 | ERCC5 (0.51) | ALDH1A1HPGDMAPTMEN1HTT | |
| SCHEMBL28808767 | 0.83 | EPHX2 (0.59) | ALDH1A1HPGDMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919841-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | RES TRIANGLE INST (US) | 2018-08-02 | — | — | US | disclosed |
| US-9562001-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2017-02-07 | — | — | US | disclosed |
| US-8816095-B2 | Na channels, disease, and related assays and compositions | GEORGETOWN UNIVERSITY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8816095-B2 | Na channels, disease, and related assays and compositions | GEORGETOWN UNIVERSITY (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE | 2012-03-22 | — | — | US | disclosed |
| EP-2419400-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20110230442-A1 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230442-A1 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2010121022-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010027641-A2 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010019963-A2 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | ALDH1A1 521/4885HPGD 2548/4885HSD17B3 211/4885 |
| US-10919841-B2 | Monoamine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | ALDH1A1 521/4885HPGD 2548/4885HSD17B3 211/4885 |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | ALDH1A1 521/4885HPGD 2548/4885HSD17B3 211/4885 |
| US-20110230442-A1 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | CACNA1C, CACNA1B, CACNA1A | ALDH1A1 3821/4885HPGD 2866/4885HSD17B3 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.